Story perspectives

New Amperia Platform Enhances Gene Therapy Capsid Measurement

10/30/2025

25 3

Summary

Story summary

Dr. Ruizhi Wang, CEO of Abselion, discussed the Amperia benchtop platform, which aims to improve capsid quantification in gene therapy.
Accurate AAV capsid measurement is crucial for safe therapies, since capsid heterogeneity can affect production and immune responses.
The Amperia platform offers a standardized approach with defined reagents and workflows to improve reliability across laboratories.
Wang emphasized aligning analytical methods to support the gene therapy field's advancement.

1 of 1

Story summary

Dr. Ruizhi Wang, CEO of Abselion, discussed the Amperia benchtop platform, which aims to improve capsid quantification in gene therapy.
Accurate AAV capsid measurement is crucial for safe therapies, since capsid heterogeneity can affect production and immune responses.
The Amperia platform offers a standardized approach with defined reagents and workflows to improve reliability across laboratories.
Wang emphasized aligning analytical methods to support the gene therapy field's advancement.